Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema

Ophthalmologica

Volumn 231, Issue 1, 2013, Pages 16-22

  Santos, Ana Rita ^a   Gomes, Sara Cristina ^b   Figueira, João ^a,b,c   Nunes, Sandrina ^a   Lobo, Conceição Lopes ^a,b,c   Cunha Vaz, José Guilherme ^a,b  

^a ASSOCIATION FOR INNOVATION AND BIOMEDICAL RESEARCH ON LIGHT AND IMAGE AIBILI   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

Author keywords

Diabetic retinopathy; Macular edema; Optical coherence tomography; Treatment outcome; Vascular endothelial growth factor inhibitors; Visual acuity

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CENTRAL RETINAL THICKNESS; DIABETIC MACULAR EDEMA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; TREATMENT RESPONSE; VISUAL ACUITY; CLINICAL ARTICLE; EPIRETINAL MEMBRANE; MACULAR THICKNESS; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA DETACHMENT; RETINA EDEMA; RETINAL THICKNESS; RETROSPECTIVE STUDY; VISUAL IMPAIRMENT;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETIC RETINOPATHY; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; ORGAN SIZE; RETINA; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84898465101     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000355487     Document Type: Article

References (33)

1. Fong DS: Retinopathy in diabetes. Diabetes Care 2004; 27:S84-S87. (Pubitemid 38197476)
2. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL: The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464-1474. (Pubitemid 15197017)
3. Frank RN: Diabetic retinopathy. N Engl J Med 2004; 350: 48-58. (Pubitemid 38032183)
4. Parravano M, Menchini F, Virgili G: Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema. Cochrane Database Syst Rev 2009; 4:CD007419.
5. Lang GE: Diabetic macular edema. Ophthalmologica 2012; 227(suppl 1):21-29.
6. Marmor MF: Mechanisms of fluid accumulation in retinal edema. Doc Ophthalmol 1999;97: 239-249.
7. Massin P, Bandello F, Garweg JG, et al: Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33: 2399-2405.
8. Mitchell P, Bandello F, Schmidt-Erfurth U, Lang GE, Massin P, Schlingemann RO, et al: The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
9. Nguyen QD, Shah SM, Khwaja A, Channa R, Hatef E, Do DV, et al: Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2010; 117: 2146-2151.
10. Elman MJ, Aiello LP, Beck RW, et al: Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077. e1035.
11. Elman M, Bressler N, Qin H, Beck R: Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118: 609-614.
12. Chun DW, Heier JS, Topping TM, Duker JS, Bankert JM: A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 2006; 113: 1706-1712. (Pubitemid 44442451)
13. Nguyen QD, Shah SM, Heier JS, Do DV, Lim J, Boyer D, et al: Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 2009; 116: 2175-2181.
14. Brown DM, Nguyen QD, Marcus DM, Boyer DS, Patel S, et al: Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-2022.
15. Heier JS: Neovascular age-related macular degeneration - individualizing therapy in the era of anti-angiogenic treatments. Ophthalmology 2013; 120:S23-S25.
16. Diabetic Retinopathy Clinical Research Network, Aiello LP, Beck RW, Bressler NM, et al: Rationale for the diabetic retinopathy clinical research network treatment protocol for center- involved diabetic macular edema. Ophthalmology 2011; 118:e5-e14.
17. Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini A, Brito M, et al: Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009; 116: 1488-1497.
18. Salam A, DaCosta J, Sivaprasad S: Anti-vascular endothelial growth factor agents for diabetic maculopathy. Br J Ophthalmol 2010; 94: 821-826.
19. Fujimoto JG, Drexler W: Introduction to optical coherence tomography; in Drexler W, Fujimoto JG (eds): Optical Coherence Tomography - Technology and Applications. Biological and Medical Physics, Biomedical Engineering. Berlin, Springer, 2008, pp 1-45.
20. Drexler W, Fujimoto JG: State-of-the-art retinal optical coherence tomography. Prog Retin Eye Res 2008;27:45-88. (Pubitemid 351165776)
21. Schimel AM, Fisher YL, Flynn HW: Optical coherence tomography in the diagnosis and management of diabetic macular edema: time-domain versus spectral-domain. Ophthalmic Surg Lasers Imaging 2011; 42(suppl):S41-S55.
22. Avery RL, Pearlman J, Pieramici DJ, Rabena MD, Castellarin A, Nasir M, et al: Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113:e1-e15.
23. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic conditions: basic concepts, clinical features and management. Prog Retin Eye Res 2008; 27: 622-647.
24. Nguyen QD, Tatlipinar S, Shah SM, et al: Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 2006; 142: 961-969.
25. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985; 103: 1796-1806.
26. Soliman W, Sander B, Jorgensen TM: Enhanced optical coherence patterns of diabetic macular oedema and their correlation with the pathophysiology. Acta Ophthalmol Scand 2007; 85: 613-617. (Pubitemid 47316759)
27. Sivaprasad S, Ikeji F, Xing W, Lightman S: Tomographic assessment of therapeutic response to uveitic macular oedema. Clin Exp Ophthalmol 2007; 35: 719-723. (Pubitemid 350090528)
28. Otani T, Kishi S, Maruyama Y: Patterns of diabetic macular edema with optical coherence tomography. Am J Ophthalmol 1999; 127: 688-693. (Pubitemid 29266745)
29. Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A: Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 2003; 135: 169-177. (Pubitemid 36151793)
30. Gaucher D, Tadayoni R: Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema. Am J Ophthalmol 2005; 807-814.
31. Koizumi H, Spaide RF, Fisher YL, Freund KB, Klancnik JM, Yannuzzi L: Three-dimensional evaluation of vitreomacular traction and epiretinal membrane using spectral-domain optical coherence tomography. Am J phthalmol 2008; 145: 509-517.
32. Mirzo Luca RG, Johnson MW, Jampol LM: Optical coherence tomography use in evaluation of the vitreoretinal interface: a review. Surv Ophthalmol 2007; 52: 397-421. (Pubitemid 46898548)
33. Bandello F, Cunha-Vaz J, Chong NV, Lang GE, Massin P, Mitchell P, et al: New approaches for the treatment of diabetic macular oedema: recommendations by an expert panel. Eye 2012; 26: 485-493.